LONDON, February 26, 2013 /PRNewswire/ --
Drug companies work on precarious grounds. Their stock may go up and down based on the future expectations about their drugs. Keryx Biopharmaceuticals Inc. (NASDAQ: KERX) scored new 52-week high despite having no drug in the market. The stock is basically moving up on the expectation of its drug candidate receiving FDA approval. On the other hand, Sanofi (NYSE: SNY) also reached a new high on the strength of its existing and potential drug portfolio. StockCall initiated free in-depth technical analysis on Sanofi and Keryx Biopharmaceuticals which are currently available upon sign up at
Keryx Biopharmaceuticals Inc. Touches New 52-Week High
Keryx Biopharmaceuticals Inc. recently reported positive results from the third phase of its Zerenex trials. The drug is designed for treating patients with End Stage Renal Disease. Zerenex may be presented for the FDA approval in 2014. The company is already arranging financing for launching the drug as it offered 55 million shares in a public offering in January. Sign up for the free technical analysis on Sanofi at
Keryx's stock is up 108 percent in the past 52 weeks and with the positive news about its drug candidate the momentum is likely to continue. The company has been at the center of a number of lawsuits. However, the cases are expected to have only minor negative impact on the company.
Another negative point relates to the company's dependence on its only drug candidate. Whether the drug will receive FDA's approval or not is up for speculation, the drug's potential to generate revenue after receiving approval is also open to scrutiny. In case, the drug fails to get approved or fails to perform well after approval, the company's fortunes will be in a grave danger.
Despite all the tailwinds, the company is in a solid financial position. It is preparing well to arrange funding for the proper launch of the drug. Also the drug itself has very high chances of getting approved. Overall, Keryx Biopharma seems to have a promising future ahead.
Sanofi Reports Flat Revenue for Fourth Quarter
Sanofi has been hitting its new-high recently. The pharma company's Lixisenatide also got accepted for review by FDA. The company also received FDA approvals for its drugs last year and its stock is expected to perform well on the back of the performance of new drugs. The company stock is up 23 percent in the past 52 weeks and it also offers 3.62 percent dividend yield. Overall, the stock offers an attractive investment opportunity for both value and income investors. Berkshire Hathaway holds interest in the company, underlining the growth potential of its stock. Abrams Capital Management also has stake in Sanofi. Download the free report on Keryx Biopharmaceuticals Inc. by registering at
The company has impressive prospects for the future and it is also looking to grow through acquisitions. Sanofi is said to be interested in acquiring Regeneron Pharmaceuticals Inc. Both companies are already collaborating for developing cancer therapy. For its fourth quarter, Sanofi reported flat revenue. It also provided conservative estimates. However, the overall scenario for the company looks bright and its stock is expected keep up the momentum. The company is also looking to get FDA approval for Lemtrada and it may prove to be a positive catalyst for the stock.
StockCall.com is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines. Sign up today to talk to our financial analyst at